Latest stories on KROS
Keros Therapeutics files $350M mixed securities shelf
The Fly28 · bearishgeneral
Keros Therapeutics Launches $5M Share Buyback Following Development Milestone Payment
MarketWatch63 · neutralgeneral
Keros Therapeutics launches $5M share buyback after $20M milestone
Seeking Alpha62 · neutralgeneral
Keros Therapeutics announces $5M share repurchase program after Takeda payment
The Fly71 · bullishgeneral
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
GlobeNewswire71 · bullishgeneral
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
StockTitan71 · bullishgeneral
Keros Therapeutics price target lowered to $17 from $20 at BofA
The Fly38 · neutralanalyst
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
Keros Therapeutics Reports Second Quarter 2026 Financial Results
StockTitan50 · neutralgeneral
Keros Therapeutics to Receive $20 Million Development Milestone Payment From Takeda
Morningstar73 · bullishproduct/pr
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
StockTitan63 · neutralgeneral
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Quartz58 · neutralgeneral
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
TipRanks34 · bearishgeneral
Keros Therapeutics Appoints Anne Prener to Board
TipRanks55 · neutralgeneral
Keros Therapeutics, Inc. (KROS) files 8-K
SEC 8-K50 · neutralgeneral
Keros Therapeutics Appoints Anne Prener to its Board of Directors | KROS Stock News
StockTitan56 · neutralgeneral
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Keros Therapeutics Stockholders Approve Directors and Governance Matters
TipRanks50 · neutralgeneral
Keros Therapeutics CEO to Present at Goldman Sachs Conference
TipRanks55 · neutralgeneral
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference | KROS Stock News
StockTitan56 · neutralproduct/pr
Keros Therapeutics GAAP EPS of -$1.21 misses by $0.19, revenue of $0.37M misses by $1.32M
Seeking Alpha34 · bearishearnings